19 October 2026
strategyland.uk
Frasers Group PLC (FRAS)
Rank #264 of 280 - Consumer Cyclicals - UK Equities
Frasers Group PLC
Factor Analysis Summary
Editorial assessment generated from Frasers Group PLC's live factor scores and sector positioning.
Based on Strategyland's proprietary 7-factor analysis, Frasers Group PLC (FRAS.L) currently holds an overall rank of #264 out of 280 FTSE 100 constituents, reflecting its weighted composite score across liquidity, valuation, profitability, solvency, asset efficiency, market trading, and technical dimensions.
Key strengths include asset efficiency, where it demonstrates highly efficient capital deployment, converting assets into revenue and returns effectively, and technical (RSI 68.8), where it demonstrates generally favourable technical indicators with price holding above key moving averages.
Areas requiring attention include profitability (ROE 15.6%, net margin 6.6%), where compressed margins and weak returns on equity weigh on the earnings profile, as well as market trading, where low relative volume or adverse volatility patterns may deter momentum-oriented investors.
Within the Consumer Cyclicals sector, Frasers Group PLC sits at composite rank #264, trailing the Consumer Cyclicals peer average (rank 44). It ranks behind all 6 tracked Consumer Cyclicals peers in our model.
The composite profile is weighed down by 5 below-average factor scores, with profitability (rank 233/280) representing the most significant drag on its #264 overall standing.
Strongest Factors
- Asset Efficiency — Rank 56/280 (top quartile)
- Technical — Rank 82/280 (above average)
- Valuation — Rank 190/280 (below average)
Weakest Factors
- Profitability — Rank 233/280 (below average)
- Market Trading — Rank 228/280 (below average)
Score Analysis
Frasers Group PLC is ranked #264 out of 280 UK stocks. Lower factor scores indicate better performance in that category.
Factor Breakdown
1. Liquidity
Score: 210/280How liquid is FRAS and can it meet its short-term obligations?
Key Liquidity Metrics
Overall Liquidity Rank
2. Valuation
Score: 190/280Is FRAS undervalued compared to its peers and fair value metrics?
Key Valuation Metrics
Dividend
FRAS does not currently pay a significant dividend.
3. Profitability
Score: 233/280How profitable is FRAS relative to its peers?
EPS Growth
4. Solvency
Score: 201/280How strong is FRAS's balance sheet and financial position?
Key Solvency Metrics
Altman Z-Score
5. Asset Efficiency
Score: 56/280How efficiently does FRAS deploy its assets and intellectual capital?
Overall Asset Efficiency Rank
6. Market Trading
Score: 228/280How liquid and actively traded is FRAS?
Trading Volume
7. Technical
Score: 82/280What do the technical indicators say about FRAS?
RSI (14 Day)
Moving Averages
Risk Metrics
Peer Comparison
How does FRAS compare to other Consumer Cyclicals stocks?
Overall Rank Comparison
Factor Score Comparison
Similar Stocks
Other top-ranked stocks in the Consumer Cyclicals sector
LiveCatch Healthcare Events Before the Market Moves
SEC filings, FDA approvals, clinical trials, and regulatory events - scored for significance across 4 global markets.
Methodology Note
The analysis presented for Frasers Group PLC is produced using Strategyland's proprietary 7-factor quantitative model, which evaluates each stock across Liquidity, Valuation, Profitability, Solvency, Asset Efficiency, Market Trading, and Technical dimensions. Individual factor scores and the composite rank reflect relative rankings within the FTSE 100 universe — a lower rank number indicates stronger performance in that category.
Underlying financial and market data is sourced from LSEG (London Stock Exchange Group) and processed through our scoring engine. Scores are recalculated as new data becomes available and should be interpreted as a systematic screening output, not a forecast of future share price performance.
This content is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance and factor rankings are not indicative of future results. Please read our Risk Disclaimer before making any investment decisions.
© 2026 Strategyland by Khurram. All rights reserved.
